137 related articles for article (PubMed ID: 32352015)
1. Integrated Analysis Identifies an Immune-Based Prognostic Signature for the Mesenchymal Identity in Gastric Cancer.
Peng D; Gu B; Ruan L; Zhang X; Shu P
Biomed Res Int; 2020; 2020():9780981. PubMed ID: 32352015
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer.
Zhang B; Wang L; Liu Z; Shao B; Jiang W; Shu P
Medicine (Baltimore); 2020 Jun; 99(25):e20617. PubMed ID: 32569190
[TBL] [Abstract][Full Text] [Related]
3. Integrative network analysis identifies an immune-based prognostic signature as the determinant for the mesenchymal subtype in epithelial ovarian cancer.
Sheng M; Tong H; Lu X; Shanshan N; Zhang X; Reddy BA; Shu P
Medicine (Baltimore); 2020 Oct; 99(41):e22549. PubMed ID: 33031300
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
5. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
Zhang C; Li D; Yu R; Li C; Song Y; Chen X; Fan Y; Liu Y; Qu X
Front Immunol; 2021; 12():651033. PubMed ID: 34054812
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of a 14 immune-related gene pair signature to predict the prognosis and immune features of gastric cancer.
Liu C; Chen B; Huang Z; Hu C; Jiang L; Zhao C
Int Immunopharmacol; 2020 Dec; 89(Pt B):107074. PubMed ID: 33049494
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
[No Abstract] [Full Text] [Related]
8. Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study.
Zhu L; Wang H; Jiang C; Li W; Zhai S; Cai X; Wang X; Liao L; Tao F; Jin D; Chen G; Xia Y; Mao JH; Li B; Wang P; Hang B
EBioMedicine; 2020 Nov; 61():103023. PubMed ID: 33069062
[TBL] [Abstract][Full Text] [Related]
9. An immune-related gene signature predicts prognosis of gastric cancer.
Jiang B; Sun Q; Tong Y; Wang Y; Ma H; Xia X; Zhou Y; Zhang X; Gao F; Shu P
Medicine (Baltimore); 2019 Jul; 98(27):e16273. PubMed ID: 31277152
[TBL] [Abstract][Full Text] [Related]
10. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.
Chen T; Yang C; Dou R; Xiong B
Cancer Med; 2021 Sep; 10(18):6546-6560. PubMed ID: 34382341
[TBL] [Abstract][Full Text] [Related]
12. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of an autophagy-based signature in colorectal cancer.
Wang L; Jiang X; Zhang X; Shu P
Medicine (Baltimore); 2021 Apr; 100(13):e25148. PubMed ID: 33787596
[TBL] [Abstract][Full Text] [Related]
16. Gene expression signature-based prognostic risk score in gastric cancer.
Cho JY; Lim JY; Cheong JH; Park YY; Yoon SL; Kim SM; Kim SB; Kim H; Hong SW; Park YN; Noh SH; Park ES; Chu IS; Hong WK; Ajani JA; Lee JS
Clin Cancer Res; 2011 Apr; 17(7):1850-7. PubMed ID: 21447720
[TBL] [Abstract][Full Text] [Related]
17. Predictive and Prognostic Value of an MicroRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy.
Cheng X; Wei H; Zhang S; Zhang F
DNA Cell Biol; 2021 Nov; 40(11):1428-1444. PubMed ID: 34767733
[TBL] [Abstract][Full Text] [Related]
18. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
[TBL] [Abstract][Full Text] [Related]
19. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
